STOCK TITAN

Vanguard realignment leaves Arvinas (ARVN) ownership listed as 0 shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 5 on a Schedule 13G/A reporting beneficial ownership of 0 shares of Arvinas Inc common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026

The filing cites SEC Release No. 34-39538 and states certain Vanguard subsidiaries will report beneficial ownership separately following the realignment. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Realignment reduced reported Vanguard ownership to zero on file.

The amendment lists 0 shares and 0% beneficial ownership of Arvinas common stock; it attributes the change to an internal realignment effective January 12, 2026 and reliance on SEC Release No. 34-39538.

Cash‑flow treatment and any reallocated holdings by specific Vanguard subsidiaries are not disclosed in the excerpt; subsequent filings from Vanguard subsidiaries may show where previously aggregated holdings were re-reported.

Administrative ownership disaggregation, not a transaction by Arvinas or Vanguard itself.

The filing is administrative: it explains that subsidiaries/business divisions will report separately and that The Vanguard Group "no longer has, or is deemed to have, beneficial ownership" over those securities under the cited SEC release.

This filing does not state any acquisition or disposition by Arvinas or a change in the company's outstanding shares; it documents a reporting change by a large institutional filer.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does ARVN Schedule 13G/A Amendment No. 5 say about Vanguard's holdings?

It states The Vanguard Group reports beneficial ownership of 0 shares of Arvinas common stock, representing 0% of the class. The amendment attributes this reporting position to an internal realignment effective January 12, 2026.

Why did The Vanguard Group report zero ownership in the ARVN filing?

The filing explains an internal realignment on January 12, 2026 and reliance on SEC Release No. 34-39538, after which certain subsidiaries report beneficial ownership separately from The Vanguard Group.

Does the amendment indicate Vanguard sold Arvinas shares (ARVN)?

No. The amendment describes a reporting change due to internal realignment and the cited SEC release; it does not state any sale, purchase, or transfer of Arvinas shares by The Vanguard Group in the excerpt provided.

Who signed the ARVN Schedule 13G/A Amendment No. 5 and when?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with the signature date shown as 03/26/2026. The filing lists The Vanguard Group's Malvern, PA address.

Does the filing show which Vanguard subsidiaries now report Arvinas holdings?

The amendment states subsidiaries or business divisions will report separately pursuant to the cited SEC release but does not name specific subsidiaries or provide their individual holdings in the provided excerpt.
Arvinas

NASDAQ:ARVN

View ARVN Stock Overview

ARVN Rankings

ARVN Latest News

ARVN Latest SEC Filings

ARVN Stock Data

698.45M
58.61M
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN